Hutchison China MediTech to partner with Nestle subsidiary in healthcare JV
Nestlé Health Science SA, a fully-owned subsidiary of Nestlé SA, and Hutchison China MediTech have announced that all regulatory approvals required for the establishment of a 50/50 joint venture Nutrition Science Partners Limited have been received.
Nestl Health Science SA, a fully-owned subsidiary of Nestl SA, and Hutchison China MediTech have announced that all regulatory approvals required for the establishment of a 50/50 joint venture Nutrition Science Partners Limited have been received.
Hutchison China MediTech said that the purpose of the joint venture would be to research, develop, manufacture and market novel medicines and nutritional products derived from botanical plant origins.
The company added that Nutrition Science Partners would focus on gastrointestinal indications and could in the future expand into the metabolic disease and brain health areas.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Hutchison China MediTech's share price was up 3.85% to 526.50p at 11:13 on Friday.
MF
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Should investors fear the “September effect” in stock markets?
The first month after the summer holidays can be volatile for stock markets. Are investors right to fear the September effect?
By Katie Williams Published
-
Asos shares jump 20% after agreeing to sell Topshop and Topman brands
Asos is launching a joint venture with Denmark’s Heartland group to purchase the Topshop and Topman brands - is it time to buy?
By Chris Newlands Published